# Clinical Trial Landscape: 08_lung_squamous_pd_l1_high

*Generated: 2026-01-05 18:31:12*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 10

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1 | 28 | █████ 28.0% |
| Phase 1/Phase 2 | 25 | █████ 25.0% |
| Phase 2 | 21 | ████ 21.0% |
| Phase 3 | 12 | ██ 12.0% |
| Unknown | 7 | █ 7.0% |
| Not Applicable | 4 |  4.0% |
| Phase 2/Phase 3 | 3 |  3.0% |

## Status Distribution

- **Recruiting**: 97 (97.0%)
- **Not yet recruiting**: 3 (3.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 8 |
| Merck Sharp & Dohme LLC | 6 |
| Seagen, a wholly owned subsidiary of Pfizer | 3 |
| AstraZeneca | 3 |
| Vanderbilt-Ingram Cancer Center | 2 |
| Fox Chase Cancer Center | 2 |
| SWOG Cancer Research Network | 2 |
| City of Hope Medical Center | 2 |
| Merus N.V. | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns | 2 |
| Mayo Clinic | 2 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Megan Daly, MD | 1 |
| Precision Biologics, Inc | 1 |
| University of Missouri-Columbia | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 24 |
| Carboplatin | 18 |
| Paclitaxel | 15 |
| Biospecimen Collection | 10 |
| Nivolumab | 9 |
| Pemetrexed | 9 |
| Computed Tomography | 9 |
| Magnetic Resonance Imaging | 8 |
| Cisplatin | 7 |
| Ipilimumab | 6 |
| Nab-paclitaxel | 5 |
| Questionnaire Administration | 4 |
| Positron Emission Tomography | 4 |
| pembrolizumab | 4 |
| Docetaxel | 4 |
| Bevacizumab | 4 |
| Cemiplimab | 4 |
| Gemcitabine | 4 |
| Sacituzumab tirumotecan | 4 |
| Cyclophosphamide | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 26 |
| South Korea | 24 |
| France | 22 |
| Australia | 22 |
| United Kingdom | 19 |
| Canada | 18 |
| Italy | 18 |
| Taiwan | 17 |
| Belgium | 15 |
| Japan | 15 |
| Poland | 14 |
| Germany | 13 |
| Netherlands | 12 |
| Hungary | 11 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| squamous cell lung cancer | manual | 1.0 |
| PD-L1 TPS ≥90% squamous cell lung cancer | llm | 0.9 |
| PD-L1 TPS ≥90% NSCLC | llm | 0.9 |
| squamous cell lung cancer PD-L1 TPS ≥90% | llm | 0.9 |
| NSCLC | llm | 0.8 |
| non-small cell lung cancer | llm | 0.8 |
| PD-L1 TPS ≥90% | llm | 0.9 |
| PD-L1 90% | llm | 0.9 |
| PD-L190% | llm | 0.8 |
| PD-L1-90% | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT04266730](https://clinicaltrials.gov/study/NCT04266730) | Phase 1 | Not yet recruiting | UNC Lineberger Compr... | Phase I Trial of a Personalized and... |
| [NCT06860815](https://clinicaltrials.gov/study/NCT06860815) | Phase 2 | Recruiting | City of Hope Medical... | Pilot Study of Cemiplimab and Hepat... |
| [NCT06945484](https://clinicaltrials.gov/study/NCT06945484) | Not Applicable | Not yet recruiting | University of Utah | PILOT for The Precision Exercise Re... |
| [NCT06524544](https://clinicaltrials.gov/study/NCT06524544) | Phase 3 | Recruiting | National Cancer Inst... | A Phase III Randomized Trial of Pem... |
| [NCT06941857](https://clinicaltrials.gov/study/NCT06941857) | Phase 2 | Recruiting | Sidney Kimmel Compre... | A Phase 2 Study of NC410 and FOLFIR... |
| [NCT06865339](https://clinicaltrials.gov/study/NCT06865339) | Phase 2 | Recruiting | Nitin Ohri | TRIPL: Thoracic Radiotherapy and In... |
| [NCT06966700](https://clinicaltrials.gov/study/NCT06966700) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Open-label S... |
| [NCT06907615](https://clinicaltrials.gov/study/NCT06907615) | Phase 2 | Recruiting | Shanghai Henlius Bio... | An Open-label, Multi-center, Global... |
| [NCT06881784](https://clinicaltrials.gov/study/NCT06881784) | Phase 3 | Recruiting | Revolution Medicines... | RASolve 301: Phase 3 Multicenter, O... |
| [NCT06975293](https://clinicaltrials.gov/study/NCT06975293) | Phase 1/Phase 2 | Recruiting | STORM Therapeutics L... | Open-label, Non-randomized, Multi-c... |
| [NCT06810544](https://clinicaltrials.gov/study/NCT06810544) | Phase 1/Phase 2 | Recruiting | Tango Therapeutics, ... | A Phase 1/2, Multicenter, Open-Labe... |
| [NCT06788912](https://clinicaltrials.gov/study/NCT06788912) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | KEYMAKER-U01 Substudy 01E: A Phase ... |
| [NCT06841354](https://clinicaltrials.gov/study/NCT06841354) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Open-label S... |
| [NCT06778863](https://clinicaltrials.gov/study/NCT06778863) | Phase 1 | Recruiting | Clasp Therapeutics, ... | GUARDIAN-101: A Phase 1 Dose Escala... |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06789172](https://clinicaltrials.gov/study/NCT06789172) | Phase 1 | Recruiting | Epkin | A Phase 1, Open-label, Multicenter,... |
| [NCT06706076](https://clinicaltrials.gov/study/NCT06706076) | Phase 1/Phase 2 | Recruiting | BlossomHill Therapeu... | A Phase 1/2 Open-Label, Multicenter... |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | Phase 2/Phase 3 | Recruiting | BioNTech SE | A Phase II/III, Multisite, Randomiz... |
| [NCT06710223](https://clinicaltrials.gov/study/NCT06710223) | Phase 1 | Recruiting | University of Califo... | A Phase Ib Study of Cryoablation an... |
| [NCT06667076](https://clinicaltrials.gov/study/NCT06667076) | Phase 2 | Recruiting | Janssen Research & D... | A Phase 2b, Open-Label, Two-cohort ... |
| [NCT06747585](https://clinicaltrials.gov/study/NCT06747585) | Phase 1/Phase 2 | Recruiting | Alentis Therapeutics... | A Phase I/II, Open-Label, Multicent... |
| [NCT06692738](https://clinicaltrials.gov/study/NCT06692738) | Phase 3 | Recruiting | AstraZeneca | A Phase III, Randomized, Double-bli... |
| [NCT06660407](https://clinicaltrials.gov/study/NCT06660407) | Phase 2 | Recruiting | Mayo Clinic | Grid Radiotherapy for Advanced Non-... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06644768](https://clinicaltrials.gov/study/NCT06644768) | Phase 1/Phase 2 | Recruiting | Daiichi Sankyo | A Multicenter, Randomized, Open-Lab... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06525220](https://clinicaltrials.gov/study/NCT06525220) | Phase 3 | Recruiting | Merus N.V. | A Phase 3 Randomized, Open-label St... |
| [NCT06452277](https://clinicaltrials.gov/study/NCT06452277) | Phase 3 | Recruiting | Bayer | A Phase 3 Open-label, Randomized, A... |
| [NCT06526819](https://clinicaltrials.gov/study/NCT06526819) | Phase 1/Phase 2 | Recruiting | Sumitomo Pharma Amer... | An Open-label, Phase 1 Dose Escalat... |
| [NCT06162572](https://clinicaltrials.gov/study/NCT06162572) | Phase 1/Phase 2 | Recruiting | Servier Bio-Innovati... | A Phase 1b/2, Multicenter, Open-lab... |
| [NCT06508034](https://clinicaltrials.gov/study/NCT06508034) | Not Applicable | Recruiting | Mayo Clinic | Probiotics Preventing Immune Checkp... |
| [NCT06475807](https://clinicaltrials.gov/study/NCT06475807) | Not Applicable | Recruiting | University of Pittsb... | Cancer Nutrition Study: CaNS - A Pi... |
| [NCT06548672](https://clinicaltrials.gov/study/NCT06548672) | Phase 1 | Recruiting | Biocity Biopharmaceu... | A Phase Ia/Ib, Open-Label, Dose Esc... |
| [NCT06228066](https://clinicaltrials.gov/study/NCT06228066) | Phase 2 | Recruiting | National Cancer Inst... | A Phase II Study of Lurbinectedin W... |
| [NCT06422143](https://clinicaltrials.gov/study/NCT06422143) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | Phase 3 Study of Pembrolizumab in C... |
| [NCT06332755](https://clinicaltrials.gov/study/NCT06332755) | Phase 1 | Recruiting | LG Chem | A Phase 1a/1b, First-in-Human, Open... |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06262321](https://clinicaltrials.gov/study/NCT06262321) | Phase 2 | Recruiting | University of Roches... | Phase II Trial of Thoracic Radiothe... |
| [NCT06312176](https://clinicaltrials.gov/study/NCT06312176) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | An Open-label, Randomized Phase 3 S... |
| [NCT06150664](https://clinicaltrials.gov/study/NCT06150664) | Phase 1 | Recruiting | Compass Therapeutics | A Phase 1, Open-Label, Multiple-Asc... |
| [NCT06242470](https://clinicaltrials.gov/study/NCT06242470) | Phase 1 | Recruiting | MacroGenics | A Phase 1/1b First-in-Human, Open L... |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Phase 2 | Recruiting | Mirati Therapeutics ... | A Randomized Study of Two Dosing Re... |
| [NCT06014255](https://clinicaltrials.gov/study/NCT06014255) | Phase 2 | Recruiting | Sidney Kimmel Compre... | A Phase 2 Randomized Trial of Neoad... |
| [NCT06246110](https://clinicaltrials.gov/study/NCT06246110) | Phase 2 | Recruiting | Eikon Therapeutics | A Phase 2 Study of EIK1001 in Combi... |
| [NCT06177106](https://clinicaltrials.gov/study/NCT06177106) | Not Applicable | Recruiting | University of Arizon... | An Assessment of Acute Solar UV-ind... |
| [NCT06119581](https://clinicaltrials.gov/study/NCT06119581) | Phase 3 | Recruiting | Eli Lilly and Compan... | SUNRAY-01, A Global Pivotal Study i... |
| [NCT06131840](https://clinicaltrials.gov/study/NCT06131840) | Phase 1 | Recruiting | Seagen, a wholly own... | An Open-label Phase 1 Study to Inve... |
| [NCT05983133](https://clinicaltrials.gov/study/NCT05983133) | Phase 1 | Recruiting | Seagen, a wholly own... | A Phase 1 Study of PF-08046052/SGN-... |
| [NCT05799274](https://clinicaltrials.gov/study/NCT05799274) | Phase 1 | Recruiting | Radiopharm Theranost... | Characterizing the Radiochemical an... |
| [NCT06047379](https://clinicaltrials.gov/study/NCT06047379) | Phase 1/Phase 2 | Recruiting | Neonc Technologies, ... | An Open-label Phase 1/2 Dose Findin... |

*... and 50 more trials (see trials.csv for full list)*
